Navigation Links
MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug
Date:5/26/2011

MOUNTAIN VIEW, Calif., May 26, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults. According to the National Headache Foundation, approximately 30 million people in the United States suffer from migraine, a debilitating neurological disorder. Common symptoms of migraine include recurrent headaches, nausea, phonophobia (sensitivity to sound) and photophobia (sensitivity to light).

"This NDA submission marks a major corporate milestone for MAP Pharmaceuticals and brings us one step closer to our goal of providing the underserved migraine patient population with a potential new treatment option," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "Our comprehensive development program evaluated LEVADEX in approximately 1,000 patients for up to one year, treating nearly 10,000 migraines. If approved by the FDA, LEVADEX could potentially provide a new treatment option for migraine sufferers, including the millions of patients whose migraines are not well treated today."

The 505(b)(2) NDA submission is based on a comprehensive development program for LEVADEX, and includes efficacy and safety data from the Phase 3 FREEDOM-301 clinical trial that has been presented at scientific conferences and was recently published in Headache: The Journal of Head and Face Pain. In the FREEDOM-301 trial, patients self-administered LEVADEX at home using the Company's proprietary TEMPO® inhaler. LEVADEX contains a novel formulation of dihydroergotamine (DHE).  Patients taking LEVADEX in this pivotal trial had statistically significant improvement at two hours compared to patients on placebo for all four c
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Watson Acquires Specifar Pharmaceuticals
2. Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX® in EU
3. BioMarin to Present at the UBS Global Specialty Pharmaceuticals Conference
4. Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
5. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
6. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
7. Vanda Pharmaceuticals Reports First Quarter 2011 Results
8. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
9. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
10. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
11. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Dec. 15, 2014  Ascendis Pharma A/S, a ... to address significant unmet medical needs, today announced ... 2 pediatric study to evaluate once-weekly TransCon Growth ... GHD.  This interim analysis consists of 25 patients, ... in the study, completing all six months of ...
(Date:12/13/2014)... Washington, USA, and TAICHUNG, Taiwan (PRWEB) December 12, 2014 ... rise, despite less rosy indicators in overall global economic ... society for optics and photonics , said in a ... International Conference) on 5 December at the National Chung ... solar energy, which is being integrated into future energy ...
(Date:12/13/2014)... 2014 Research and Markets ( ... "Glucose Sensors: the Next Generation" report ... http://photos.prnewswire.com/prnh/20130307/600769 The convergence of small-scale ... hope for a better future to millions of ... measure glucose levels accurately and reliably have the ...
(Date:12/12/2014)... Pittcon is pleased to announce the ... 2,000 technical presentations offered in symposia, oral sessions, ... covers a wide range of applications such as, ... environmental, food science, fuels/energy, genomics, lab management, materials ... Technical Program begins on Sunday, March 8 and ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 2Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 3
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) ... to pursue a pivotal (Phase II/III) randomized ... in refractory,patients with head and neck cancers. ... results by the Company,s Board of Directors ...
... BOZEN, Italy, November 4 Health-Robotics today,announced ... strategic partnership with,Arabian Health Care Supply Corporation ... IV Solution provider within the Gulf,Cooperation Council ... cost-effectively automate the preparation of life-critical hazardous,and ...
... team up in specialty biologics development, TORONTO ... and,Therapure BioPharma Inc. have agreed to partner in ... for cancer treatments, with a goal of,advancing the ... a,marketing partner to add to its portfolio of ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial 2Health Robotics Announces Contract for its CytoCare(TM) and IV Station(TM) Robots With Arabian Health Care Supply Corporation 2Health Robotics Announces Contract for its CytoCare(TM) and IV Station(TM) Robots With Arabian Health Care Supply Corporation 3Health Robotics Announces Contract for its CytoCare(TM) and IV Station(TM) Robots With Arabian Health Care Supply Corporation 4Therapure Biopharma Inc. announces collaboration with BioVectra Inc. 2
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
(Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... in microcontroller (MCU) and touch technology solutions, today launched ... sensors with the widest V cc range ... temperature accuracy and faster I 2 C bus communication ... serial EEPROM memory making them ideal for consumer, industrial, ...
(Date:11/18/2014)... Nov. 17, 2014 The Parenteral Drug Association (PDA) ... agencies will speak and at least seven more will participate ... the Omni Shoreham Hotel in Washington D.C. ... to have significant support from the regulatory agencies in ... in our effort to help advance the use ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... the challenges of increasing demands for food from a growing ... in the journal Science ., The goal of sustainable ... the article in the journal,s Policy Forum by lead authors ... of Oxford. They say this would minimise the pressure on ...
... Large-scale network organisation in the avian forebrain Birds ... years. So it,s hardly surprising that under a microscope, the ... a mammal. Nevertheless, birds have been shown to be remarkably ... puzzles. How is it that both kinds of brain are ...
... COLLEGE STATION Texas A&M University System scientists from ... science have developed a new medium for the cultivation ... of lactobacilli metabolism can help improve feed efficiency ... the researchers. "Lactobacilli are normal residents of the ...
Cached Biology News:The balancing act of producing more food sustainably 2The balancing act of producing more food sustainably 3Frontiers news briefs: July 4 2Frontiers news briefs: July 4 3Frontiers news briefs: July 4 4Frontiers news briefs: July 4 5Frontiers news briefs: July 4 6Newly developed medium may be useful for human health, biofuel production, more 2
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
Ly-49C and Ly-49I Biotin Anti-Mouse clone 5E6, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Dog polyclonal to Porcine Pancreatic Islets of Langerhans Cells ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Pig): Sonicated crude membrane fraction of porcine p...
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
Biology Products: